Weight loss medication is set to get a game-changer with the approval of pill form Wegovy, a GLP-1 receptor agonist. This breakthrough has sparked debate among current users and healthcare professionals about its potential to make these increasingly popular treatments more affordable and accessible to those who need them. While injectable versions have shown impressive results for many patients, the prospect of an oral alternative raises new questions about convenience, cost, and access.
Sophie Bradfield, a 56-year-old lab technician from Bristol, has already seen significant weight loss using injectable GLP-1 medication. Having lost five stone since starting treatment in June last year, Bradfield hopes that a pill format could be more cost-effective. She told us that while she's content with injections, the potential for lower prices with a tablet would be a welcome change. Bradfield has used both Mounjaro and Wegovy, preferring Mounjaro but anticipating its future availability in pill form.
Currently, only one GLP-1 receptor agonist is approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) as a once-a-day tablet: Wegovy. Its manufacturer, Novo Nordisk, believes that this oral option offers greater convenience, particularly as it doesn't require refrigeration like its injectable counterpart. Emil Kongshøj Larsen, executive vice president of international operations at Novo Nordisk, says this provides patients with an additional choice that may better fit into their lifestyles and health objectives.
However, the new pill is not yet approved for use on the NHS. The National Institute for Health and Care Excellence (NICE) can only recommend a medicine for NHS use after receiving a submission for appraisal from the manufacturer. A NICE spokesperson confirmed that they are in active dialogue with Novo Nordisk but have yet to receive evidence for appraisal, meaning no recommendation for NHS use can be made at this time.
Some patients prefer the injectable version, citing concerns about the potential inconvenience of a daily pill regimen. Mick Collins, a 58-year-old cheese seller from Weston-super-Mare, currently on an NHS weight loss programme using Mounjaro, prefers his weekly injections. Having lost over two and a half stone, Collins expressed worries that a daily pill could become 'annoying' and prone to forgetfulness, sticking with the current injection method.
The broader economic implications of these medications becoming more affordable and widely accessible could be significant. Reduced obesity rates might lead to a healthier workforce, potentially decreasing the burden on the NHS and improving productivity in businesses across the UK.